Family-owned Boehringer bucks pharma trend
This article was originally published in Scrip
Boehringer Ingelheim has reported impressive sales growth of 12% for 2012, to €14.7 billion. The expansion came as the global pharma industry grew by just 1.6%, down from 4.7% in 2011. "This confirms our strategy off organic growth, with our own R&D, thereby securing the long-lasting independence of Boehringer Ingelheim," said Professor Andreas Barner, chairman of the board of managing directors.